Navigation Links
Optimer Pharmaceuticals Reports Third Quarter 2011 Financial Results
Date:11/3/2011

SAN DIEGO, Nov. 3, 2011 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) today announced the Company's financial results for the quarter ended September 30, 2011.

(Logo: http://photos.prnewswire.com/prnh/20090413/LA97352LOGO)

Optimer reported total revenues for the third quarter of 2011 of $11.1 million, compared $669,000 for the third quarter in 2010. This includes net product sales of $10.6 million recognized from the sale of DIFICID™. Optimer recognizes product sales of DIFICID upon delivery of product to its wholesalers.

  • For the quarter ended September 30, 2011, the $10.6 million in net sales to wholesalers reflected a total of 4,335 DIFICID treatments
  • 2,505 DIFICID treatments were shipped from wholesalers to hospitals, retail pharmacies and long-term care facilities in the quarter ended September 30, 2011
  • 535 hospitals had ordered DIFICID as of September 30, 2011
  • 304 hospitals had placed DIFICID on formulary, and 346 hospital formulary reviews were pending as of October 21, 2011.

  • "In only a few months since our first DIFICID sale on July 19th we've seen significant interest in DIFICID converting into uptake and adoption. We reported $10.6 million in sales to our wholesalers in the third quarter, and we expect continued strong uptake as the launch progresses," said Pedro Lichtinger, President and CEO of Optimer. "This confirms our belief that DIFICID meets the need for a Clostridium difficile-associated diarrhea treatment addressing the problem of recurrence by providing a sustained clinical response. As the medical community becomes more familiar with and recognizes the value of DIFICID, we anticipate that adoption will continue."Optimer reported a net loss for the third quarter of 2011 of $26.4 million, or ($0.57) 
    '/>"/>

    SOURCE Optimer Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related biology technology :

    1. Optimer Pharmaceuticals Reports First Quarter 2009 Financial Results
    2. Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI
    3. Optimer Pharmaceuticals to Present at June 2009 Investor Conferences
    4. Optimer Pharmaceuticals to Present at the Canaccord Adams 29th Annual Global Growth Conference
    5. Optimer Pharmaceuticals Reports Second Quarter 2009 Financial Results
    6. Optimer Pharmaceuticals Announces Presentations of Additional Phase 3 Fidaxomicin and Prulifloxacin Data at Upcoming ICAAC Annual Meeting
    7. Optimer Pharmaceuticals to Present at September 2009 Investor Conferences
    8. Optimer Pharmaceuticals Reports Third Quarter 2009 Financial Results
    9. Optimer Pharmaceuticals Phase 3 Clinical Trials show Fidaxomicin is Superior to Vancomycin in Treatment of Recurrent Clostridium difficile Infection (CDI); Data Presented at ICAAC
    10. Optimer Announces Presentation of Additional Data from Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection (CDI) Presented at ICAAC
    11. Optimer Pharmaceuticals Announces Presentations at Upcoming IDSA Annual Meeting
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/25/2014)...  Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD ) ... and commercialization of a once-daily, oral therapy for the ... financial results for the period ended June 30, 2014. ... Reported cash and cash equivalents totaling $37.4 million on ... 2013.  , Reported a net loss of $3.9 ...
    (Date:7/24/2014)... NY - July 24, 2014 -- Keryx Biopharmaceuticals, Inc. ... the long-term, randomized, active control Phase 3 study of ... phosphate binder, for the treatment of hyperphosphatemia in patients ... study (PhosphatE binding and iRon delivery with FErric CiTrate ... Journal of the American Society of Nephrology ( ...
    (Date:7/24/2014)... MENLO PARK, Calif. , July 24, 2014 ... biotechnology company in the emerging field of regenerative ... live webcast of a presentation to investors on ... 1:30 p.m. PDT.  The presentation will include an ... pipeline. To access the webcast, visit http://www.ustream.tv/channel/asterias-biotherapeutics ...
    (Date:7/24/2014)... Quantum computers have yet to materialise. Yet, scientists ... making such computers faster. One such approach relies ... controlled by applying an electric field. A new ... coherently coupled quantum dots (TQDs) with electrical impulses ... for example, should TQDs be used as quantum ...
    Breaking Biology Technology:Galmed Pharmaceuticals Reports First Half 2014 Financial Results 2Galmed Pharmaceuticals Reports First Half 2014 Financial Results 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 4Galmed Pharmaceuticals Reports First Half 2014 Financial Results 5Galmed Pharmaceuticals Reports First Half 2014 Financial Results 6Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 4Asterias Biotherapeutics Announces Live Investor Webcast 2Asterias Biotherapeutics Announces Live Investor Webcast 3Asterias Biotherapeutics Announces Live Investor Webcast 4
    ... hardest substance in the human body is moved by its ... a schnitzel, enormous strengths are working on the surface of ... also goes for dentures, inlays or bridges", glass chemist Prof. ... (Germany) says. After all, these are worn as much as ...
    ... 2012 Tengion, Inc. (NASDAQ: TNGN ... it has completed the relocation of its corporate ... existing facility in Winston-Salem, North Carolina.  The relocation ... which was designed to fund the Company,s lead ...
    ... Jan. 5, 2012  Superior Controls, Inc. has been ... Control Engineering magazine.  Each year, the worldwide competition ... exceptional technical expertise, business skills and customer satisfaction. ... 50 applications from industrial systems integrators throughout the ...
    Cached Biology Technology:Nanocrystals make dentures shine 2Tengion Announces Relocation of Corporate Headquarters to Current Facility in Winston-Salem, North Carolina 2Tengion Announces Relocation of Corporate Headquarters to Current Facility in Winston-Salem, North Carolina 3Tengion Announces Relocation of Corporate Headquarters to Current Facility in Winston-Salem, North Carolina 4Superior Controls of Seabrook, NH Named System Integrator of the Year for 2012 by Control Engineering Magazine 2
    (Date:7/25/2014)... colonial era, 100,000s of people lived on the land ... fire to control the availability of plants they used ... to use fire to maintain desired habitat and natural ... Forest Service,s Pacific Southwest Station, will lead a ... Refuge during the Ecological Society of America,s 99th Annual ...
    (Date:7/25/2014)... raging this summer and some of the smoke from those ... image collected by the Moderate Resolution Imaging Spectroradiometer (MODIS) aboard ... smoke has descended over the Great Lakes region of the ... image from July 23, 2014 (first image feature highlighted below) ... off southeastward. In the image, it is over Manitoba ...
    (Date:7/25/2014)... online in the International Journal of Cancer ... cervical cancer based on findings showing successful reduction in ... discrete population of cells in the cervix. , ... squamocolumnar junction cells, or SCJ cells. These cells reside ... the origins of cervical cancer. A research team co-led ...
    Breaking Biology News(10 mins):Fire ecology manipulation by California native cultures 2Fire ecology manipulation by California native cultures 3Clearing cells to prevent cervical cancer 2
    ... FARMINGTON, Conn., April 23, 2012 /PRNewswire-iReach/  -- Global ... Early Bird discounted registration for three important Boston healthcare ... Pioneers from across the rapidly maturing kinase ... of what lies ahead at the Next-Gen Kinase ...
    ... annual losses of millions of dollars and pose serious challenges ... difficult and expensive. According to T. D. Schowalter, author ... Integrated Pest Management called " Ecology and Management of ... ) in Southern Pine Forests ," preventative measures are most ...
    ... Biology 2012, Dr. Blake Rasmussen and colleagues presented a ... vs. Whey Protein Ingestion on Muscle Protein Synthesis Following ... that a protein blend (combination of soy, whey and ... muscle. Specifically, the blend of proteins in this study ...
    Cached Biology News:Attendees Save Up To $800 on Boston-area Pharmaceutical and Healthcare Conferences, Early Bird Discounts Expiring April 27 2Attendees Save Up To $800 on Boston-area Pharmaceutical and Healthcare Conferences, Early Bird Discounts Expiring April 27 3New study finds a protein combination is best to consume post-workout for building muscle 2
    assays for phosphatase, lipase, nucleoside triphosphatases (ATPase, GTPase etc). HTS and follow up studies for phosphatase inhibitors. Quantitation of phosphate content in protein, lipids, and DNA....
    ... Design with Purpose -- The ... provide the highest level of ... in an affordable, easy-to-use system. ... and workstation guarantees success with ...
    EnzChek cellulase substrate *blue fluorescent, 339/452...
    Homo sapiens 4-aminobutyrate aminotransferase Antigen: Recombinant Protein...
    Biology Products: